Neuroprotective Effects of Selegiline Agent Methamphetamine-Prompted Mood-Related Behavior Disorder Mediated Via 5-HT
D2 and 5-HT2 receptors
Selegiline
methamphetamine
neurobehavioral
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
02
2022
accepted:
27
10
2022
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
Many previous studies demonstrated that methamphetamine (METH) abuses can cause mood-related behavioral changes. Previous studies indicated neuroprotective effects of Selegiline. Seventy male Wistar rats were randomly divided into eight groups (10 rats in each group). Group 1 and Group 2 received normal saline and methamphetamine (10 mg/kg) for 21 days, respectively. Groups 3, 4, and 5 were treated simultaneously with methamphetamine and Selegiline with doses of 10, 15, and 20 mg/kg for 21 days. Groups 6 and 7 are methamphetamine-dependent groups which received 15 mg/kg of Selegiline with haloperidol (as D METH as 10 mg/kg causes reduction of rearing number, ambulation distances, time spent in central square and also number of central square entries in OFT. Also METH administration causes decreases of time spent in open arm and number of open arm entries and increases of time spent in closed arm and number of closed arm entries in EPM. In contrast, Selegiline (of 10, 15, and 20 mg/kg) inhibited behavioral effects of methamphetamine in both OFT and EPM. Also administration of haloperidol and trazodone inhibited these behavioral protective effects of Selegiline and caused decrease of OFT behaviors (rearing number, ambulation distances, time spent in central square, and also number of central square entries) and also caused decreases of spend times in open arm, number of open arm entries, and also increased closed arm time spending and number of entries in closed arm in EPM. Current research showed that Selegiline via mediation of D2 and 5-HT
Sections du résumé
Background
UNASSIGNED
Many previous studies demonstrated that methamphetamine (METH) abuses can cause mood-related behavioral changes. Previous studies indicated neuroprotective effects of Selegiline.
Methods
UNASSIGNED
Seventy male Wistar rats were randomly divided into eight groups (10 rats in each group). Group 1 and Group 2 received normal saline and methamphetamine (10 mg/kg) for 21 days, respectively. Groups 3, 4, and 5 were treated simultaneously with methamphetamine and Selegiline with doses of 10, 15, and 20 mg/kg for 21 days. Groups 6 and 7 are methamphetamine-dependent groups which received 15 mg/kg of Selegiline with haloperidol (as D
Results
UNASSIGNED
METH as 10 mg/kg causes reduction of rearing number, ambulation distances, time spent in central square and also number of central square entries in OFT. Also METH administration causes decreases of time spent in open arm and number of open arm entries and increases of time spent in closed arm and number of closed arm entries in EPM. In contrast, Selegiline (of 10, 15, and 20 mg/kg) inhibited behavioral effects of methamphetamine in both OFT and EPM. Also administration of haloperidol and trazodone inhibited these behavioral protective effects of Selegiline and caused decrease of OFT behaviors (rearing number, ambulation distances, time spent in central square, and also number of central square entries) and also caused decreases of spend times in open arm, number of open arm entries, and also increased closed arm time spending and number of entries in closed arm in EPM.
Conclusions
UNASSIGNED
Current research showed that Selegiline via mediation of D2 and 5-HT
Identifiants
pubmed: 37855005
doi: 10.4103/ijpvm.ijpvm_42_22
pii: IJPVM-14-78
pmc: PMC10580189
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78Informations de copyright
Copyright: © 2023 International Journal of Preventive Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Med Hypotheses. 2019 Dec;133:109371
pubmed: 31465975
Arch Iran Med. 2015 Sep;18(9):591-603
pubmed: 26317601
Curr Drug Abuse Rev. 2012 Sep;5(3):227-42
pubmed: 22998621
Physiol Behav. 2016 Sep 1;163:107-114
pubmed: 27143252
J Pharmacol Exp Ther. 2010 Oct;335(1):207-12
pubmed: 20622144
Iran J Basic Med Sci. 2019 Aug;22(8):856-865
pubmed: 31579440
Iran J Pharm Res. 2019 Spring;18(2):745-758
pubmed: 31531058
Neurotoxicology. 2019 May;72:74-84
pubmed: 30742852
Curr Protoc Neurosci. 2004 May;Chapter 8:Unit 8.3
pubmed: 18428606
Behav Brain Res. 2019 Feb 1;359:353-361
pubmed: 30359642
JAMA Psychiatry. 2020 Sep 1;77(9):959-966
pubmed: 32267484
Curr Protoc Pharmacol. 2010 Jun;Chapter 5:Unit 5.8
pubmed: 22294373
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
J Pharmacol Exp Ther. 2009 Jul;330(1):316-25
pubmed: 19364908
Neuropathol Appl Neurobiol. 2011 Feb;37(2):118-34
pubmed: 20946118
Iran J Med Sci. 2019 Mar;44(2):146-154
pubmed: 30936601
Physiol Behav. 2022 Feb 1;244:113652
pubmed: 34801559
Neuropeptides. 2019 Oct;77:101942
pubmed: 31272684
Naunyn Schmiedebergs Arch Pharmacol. 2017 Sep;390(9):905-917
pubmed: 28643087
PLoS One. 2012;7(7):e40187
pubmed: 22808116
Curr Opin Psychiatry. 2015 Jul;28(4):269-74
pubmed: 26001916
J Neural Transm (Vienna). 2020 May;127(5):831-842
pubmed: 31562557
Psychoneuroendocrinology. 2010 May;35(4):629-33
pubmed: 19879056
Int Rev Neurobiol. 2015;120:179-204
pubmed: 26070758
Neurobiol Dis. 2011 Jun;42(3):391-403
pubmed: 21303698
CNS Neurosci Ther. 2017 Feb;23(2):119-126
pubmed: 27762079
Int Rev Neurobiol. 2011;100:65-84
pubmed: 21971003
Curr Top Behav Neurosci. 2010;3:219-45
pubmed: 21161755
BMJ. 2015 Apr 21;350:h1771
pubmed: 25900074
Asian J Psychiatr. 2015 Aug;16:17-25
pubmed: 26123235